Nuo Therapeutics, Inc. (AURX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Nuo Therapeutics, Inc. reported revenue of $3.31M, up 142.7% from the prior year. The company ran a net loss, with a net margin of -75.8% and a gross margin of 66.9%. It held $1.85M in total assets against $2.80M in total liabilities.
Key ratios (FY2025)
66.9%
Gross margin
-76.0%
Operating margin
-75.8%
Net margin
+142.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.31M | $1.37M | $608.5K | $112.2K | $0 | $0 | $146.2K | $1.37M | $721.0K | — |
| Cost of Revenue | $1.10M | $302.8K | $126.1K | $19.2K | $0 | $0 | $114.6K | $163.0K | $1.09M | — |
| Gross Profit | $2.22M | $1.06M | $482.4K | $93.0K | $0 | $0 | $31.6K | $1.21M | -$370.0K | — |
| Operating Income | -$2.52M | -$2.46M | -$3.17M | -$3.32M | -$90.7K | -$378.1K | -$969.2K | -$1.50M | -$15.53M | — |
| Net Income | -$2.51M | -$2.32M | -$3.17M | -$3.17M | -$90.7K | -$90.9K | -$1.19M | -$1.54M | -$14.98M | — |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.08 | $-0.08 | $-0.03 | $0.30 | $-0.05 | $-0.07 | $-1.02 | — |
| Total Assets | $1.85M | $1.19M | $1.88M | $3.05M | $1.47M | $161.4K | $276.5K | $975.5K | $1.42M | $14.06M |
| Total Liabilities | $2.80M | $675.8K | $838.7K | $856.0K | $673.1K | $665.0K | $1.49M | $1.06M | $941.2K | $1.57M |
| Shareholders' Equity | -$956.6K | $513.7K | $1.04M | $2.19M | $792.8K | -$503.5K | -$1.21M | -$82.0K | $482.9K | $12.49M |
| Cash & Equivalents | $548.9K | $283.7K | $928.7K | $2.05M | $1.41M | $161.4K | $20.3K | $636.9K | $693.5K | $2.62M |
| Operating Cash Flow | -$865.0K | -$2.23M | -$3.17M | -$3.71M | -$120.0K | -$53.8K | -$921.7K | -$874.4K | -$4.90M | — |
| Capital Expenditures | $274.8K | $155.0K | $7.2K | $60.0K | $0 | $0 | $0 | — | — | — |
| Shares Outstanding | 48.18M | 46.82M | 44.24M | 41.80M | 37.12M | 30.26M | 23.72M | 23.72M | 22.72M | 9.93M |